ICIs |
Immune checkpoint inhibitors |
SGLT-2 |
Sodium-glucose cotransporter type-2 |
NLRP3 |
NOD-like receptor family pyrin domain, containing 3 |
MyD88 |
Myddosome type 88 |
PD1 |
Programmed cell death protein 1 |
PDL1 |
Programmed Death-Ligand 1 |
CTLA4 |
Cytotoxic T-Lymphocyte Antigen 4 |
AMPK |
5’ AMP-activated protein kinase |
hs-CRP |
High sensitivity C-reactive protein |
ROS |
Reactive oxygen species |
MDA |
Malondialdeyde |
p65-NF-κB |
Nuclear factor kappa-light-chain-enhancer of activated B cells |
ILs |
Interleukins |
PDGF |
Platelet-Derived Growth Factor |
VEGF |
Vascular endothelia growth factor |
TGF-β |
Transforming growth factor beta |
AGEs |
Advanced glycation end products |
CVOTs |
Cardiovascular outcome trials |
VEGF |
Vascular endothelia growth factor |
TGF-β |
Transforming growth factor beta |
AGEs |
Advanced glycation end products |